| 3.43 -0.38 (-9.97%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.24 |
1-year : | 4.89 |
| Resists | First : | 3.63 |
Second : | 4.19 |
| Pivot price | 3.25 |
|||
| Supports | First : | 2.74 |
Second : | 2.28 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 3.32 |
| MA(100) : | 3.96 |
MA(250) : | 3.47 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.4 |
D(3) : | 76.2 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 6.92 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRDX ] has closed below upper band by 36.8%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.84 - 3.87 | 3.87 - 3.88 |
| Low: | 3.32 - 3.35 | 3.35 - 3.37 |
| Close: | 3.39 - 3.43 | 3.43 - 3.46 |
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
Fri, 18 Sep 2026
GridAI Technologies Corp. (GRDX) Total Assets 2025: $48.6M, down 43.2% - Stock Titan
Fri, 18 Sep 2026
$16.5M loss on $124K sales puts GridAI (GRDX) under going concern warning - Stock Titan
Thu, 03 Sep 2026
Enterprise value to EBIT forward of GridAI Technologies Corp. – NASDAQ:GRDX - TradingView
Sun, 16 Aug 2026
Should I buy GridAI Technologies Corp. (GRDX) - Zacks Investment Research
Tue, 11 Aug 2026
GridAI Technologies (GRDX) Climbs 4.70% to $3.12, Approaching Key $3.28 Resistance Level - Gamma Squeeze - careplusvn.com
Wed, 05 Aug 2026
GridAI Technologies Corp. (NASDAQ: GRDX) Stock Price, News & Analysis - kalkine.ca
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 8.9 (%) |
| Shares Short | 119 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -6.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.54 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|